BR112014012994A2 - tablete contendo hidrato de metanossulfonato do ácido 1-ciclopropil-8-(difluorometóxi)-7-[(1r)-1-metil-2,3-diidro-1h-isoindol-5-il]-4-oxo-1, 4-diidroquinolina-3-carboxílico - Google Patents

tablete contendo hidrato de metanossulfonato do ácido 1-ciclopropil-8-(difluorometóxi)-7-[(1r)-1-metil-2,3-diidro-1h-isoindol-5-il]-4-oxo-1, 4-diidroquinolina-3-carboxílico

Info

Publication number
BR112014012994A2
BR112014012994A2 BR112014012994A BR112014012994A BR112014012994A2 BR 112014012994 A2 BR112014012994 A2 BR 112014012994A2 BR 112014012994 A BR112014012994 A BR 112014012994A BR 112014012994 A BR112014012994 A BR 112014012994A BR 112014012994 A2 BR112014012994 A2 BR 112014012994A2
Authority
BR
Brazil
Prior art keywords
tablet
isoindol
dihydroquinoline
difluoromethoxy
cyclopropyl
Prior art date
Application number
BR112014012994A
Other languages
English (en)
Portuguese (pt)
Inventor
Okada Kotaro
Kakuda Sahoe
Miyazaki Tsutomu
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of BR112014012994A2 publication Critical patent/BR112014012994A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
BR112014012994A 2011-11-30 2012-11-29 tablete contendo hidrato de metanossulfonato do ácido 1-ciclopropil-8-(difluorometóxi)-7-[(1r)-1-metil-2,3-diidro-1h-isoindol-5-il]-4-oxo-1, 4-diidroquinolina-3-carboxílico BR112014012994A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011261727 2011-11-30
PCT/JP2012/080887 WO2013081044A1 (ja) 2011-11-30 2012-11-29 １－シクロプロピル－８－（ジフルオロメトキシ）－７－［（１ｒ）－１－メチル－２，３－ジヒドロ－１ｈ－イソインドール－５－イル］－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸のメタンスルホン酸塩水和物含有錠剤

Publications (1)

Publication Number Publication Date
BR112014012994A2 true BR112014012994A2 (pt) 2017-06-13

Family

ID=48535494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012994A BR112014012994A2 (pt) 2011-11-30 2012-11-29 tablete contendo hidrato de metanossulfonato do ácido 1-ciclopropil-8-(difluorometóxi)-7-[(1r)-1-metil-2,3-diidro-1h-isoindol-5-il]-4-oxo-1, 4-diidroquinolina-3-carboxílico

Country Status (10)

Country Link
JP (1) JP6117112B2 (ja)
CN (2) CN104039322A (ja)
BR (1) BR112014012994A2 (ja)
MX (1) MX350659B (ja)
MY (1) MY169750A (ja)
PH (1) PH12014501224B1 (ja)
RU (1) RU2633477C2 (ja)
SG (1) SG11201402597WA (ja)
WO (1) WO2013081044A1 (ja)
ZA (1) ZA201403942B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017073738A1 (ja) * 2015-10-29 2017-05-04 日本臓器製薬株式会社 フェキソフェナジンを有効成分とする錠剤
TWI727036B (zh) * 2016-04-27 2021-05-11 日商富山化學工業股份有限公司 包含甲苯磺酸托氟沙星、崩解劑及酸性胺基酸之錠劑
JP7058104B2 (ja) * 2017-10-19 2022-04-21 日本化薬株式会社 アプレピタントを有効成分とする医薬錠剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
IL142642A0 (en) * 1998-11-10 2002-03-10 Bayer Ag Pharmaceutical moxifloxacin preparation
JP4370050B2 (ja) * 2000-12-04 2009-11-25 大正製薬株式会社 クラリスロマイシン錠剤およびその製造法
ES2297067T3 (es) * 2003-03-19 2008-05-01 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Composiciones farmaceuticas no higroscopicas que contienen acidos quinolinacarboxilicos de hidratados.
JP4702763B2 (ja) * 2003-07-30 2011-06-15 塩野義製薬株式会社 結晶セルロースを含有する安定な錠剤
PT1776109E (pt) * 2004-08-13 2009-03-25 Schering Plough Ltd Formulação farmacêutica que compreende um antibiótico, um triazol e um corticosteróide
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
FI20080353A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi
FI20080352A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi
JP2011068647A (ja) * 2009-08-31 2011-04-07 Kowa Co アスパラギン酸又はその塩含有固形製剤
WO2011059075A1 (ja) * 2009-11-13 2011-05-19 味の素株式会社 グルタミン酸およびアルギニンの高含有製剤

Also Published As

Publication number Publication date
PH12014501224A1 (en) 2014-09-08
RU2633477C2 (ru) 2017-10-12
RU2014126094A (ru) 2016-01-27
JP6117112B2 (ja) 2017-04-19
WO2013081044A1 (ja) 2013-06-06
MX2014006378A (es) 2014-10-13
CN104039322A (zh) 2014-09-10
JPWO2013081044A1 (ja) 2015-04-27
PH12014501224B1 (en) 2014-09-08
MX350659B (es) 2017-09-13
MY169750A (en) 2019-05-15
CN109662952A (zh) 2019-04-23
ZA201403942B (en) 2015-08-26
SG11201402597WA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
PH12015500460B1 (en) Coated pharmaceutical composition containing regorafenib
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
PH12015501015B1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
TN2012000261A1 (en) Aerosol formulation for copd
BR112014012994A2 (pt) tablete contendo hidrato de metanossulfonato do ácido 1-ciclopropil-8-(difluorometóxi)-7-[(1r)-1-metil-2,3-diidro-1h-isoindol-5-il]-4-oxo-1, 4-diidroquinolina-3-carboxílico
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
NZ701428A (en) New alfentanil composition for the treatment of acute pain
BR112013025273A2 (pt) composição de líquidos de mentol
PH12014501104B1 (en) Complex antibacterial composition for animals
UY34847A (es) Preparacion sólida
NZ707033A (en) Dispersible nimorazole tablet
TH153154A (th) ยาเม็ดซึ่งมี 1-ไซโคลโพรพิล-8-(ไดฟลูออโรเมธอกซี)-7-[(1r)-1-เมธิล-2,3-ไดไฮโดร-1h-ไอโซอินโดล-5-อิล]-4-ออกโซ-1,4-ไดไฮโดรควิโนลีน-3-คาร์บอกซิลิคแอซิดมีเธนซัลโฟนิคแอซิดไฮเดรท
AR122178A2 (es) Composición farmacéutica líquida y proceso para prepararla
SA515360445B1 (ar) قرص قابل للتشتيت
UA103450C2 (ru) Фолат-конъюгированный ферроцен как биологически активное соединение медицинского назначения
TN2013000515A1 (en) Notch pathway signaling inhibitor compound
IN2013MU01251A (ja)
NZ712318A (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations
IN2013MU01252A (ja)
DK201270714A (en) Dispersible tablet

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]